Yu Cao is an Oncology physician. OpenAlex indexes 66 publications with 1,255 citations (h-index 18); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
6202 Harry Hines Blvd
Dallas, TX 75390
Telephone
214-645-4673Provider last certified this registry record 28 Aug 2024.
Clinical trials
- A Study of ZT002 Injection in Adult Chinese Subjects With Type 2 Diabetes Mellitus (T2DM)
Sponsor: Beijing QL Biopharmaceutical Co.,Ltd
- Comparative Pharmacokinetic Study of Pirfenidone Modified-Release Tablets and Pirfenidone Tablets in Healthy Subjects Under Fed Conditions
Sponsor: Overseas Pharmaceuticals, Ltd.
- Comparative Pharmacokinetic(PK) Study of Pirfenidone Modified-Release Tablets and Pirfenidone Tablets in Healthy Subjects Under Fed Conditions
Sponsor: Overseas Pharmaceuticals, Ltd.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Gilead Sciences, Inc.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
29.6%Serotonin-3 Receptor Antagonist9.5%Ondansetron Odt100%Part D≥16 patientsProton pump inhibitor9%Pantoprazole Sodium100%Part D<11 patients+ 2 more classes in this area
Nervous system
25.6%Phenothiazine14.1%Prochlorperazine Maleate100%Part D≥20 patientsOpioid Agonist6%Oxycodone Hcl100%Part D<11 patients+ 1 more class in this area
Cancer & immunology
24.6%Kinase inhibitor24.6%Tagrisso100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Down-regulating HDAC2-LTA4H pathway ameliorates renal ischemia-reperfusion injury
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
2025 - Enhancing efficacy and mitigating toxicity of Semen Strychni: From traditional practices to modern pharmaceutical innovations
Journal of Ethnopharmacology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”